<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="4.3.2">Jekyll</generator><link href="https://www.p3sysbiolab.org/feed.xml" rel="self" type="application/atom+xml" /><link href="https://www.p3sysbiolab.org/" rel="alternate" type="text/html" /><updated>2026-02-14T13:48:02+00:00</updated><id>https://www.p3sysbiolab.org/feed.xml</id><title type="html">P3 Systems Biology Lab</title><entry><title type="html">Grant awarded</title><link href="https://www.p3sysbiolab.org/2026/02/14/GrantNews-1.html" rel="alternate" type="text/html" title="Grant awarded" /><published>2026-02-14T00:00:00+00:00</published><updated>2026-02-14T13:47:29+00:00</updated><id>https://www.p3sysbiolab.org/2026/02/14/GrantNews-1</id><content type="html" xml:base="https://www.p3sysbiolab.org/2026/02/14/GrantNews-1.html"><![CDATA[<p>Our collaborative project titled “NPM1 Mutation Specific Therapeutic Vulnerabilities in Acute Myeloid Leukemia” has been selected as an awardee for Hematologic Malignancies Translational Research Team (HM-TRT) Pilot Funding FY2026 ($25,000). This project is a collaboration between Dr. Francine Garrett-Bakelman, Dr. Subhash Prajapati and P3SysBioLab. Our undergraduate, Beckett Lisle contributed to the proposal and will work on this project.
Congratulations Team!</p>]]></content><author><name>BB Paudel</name></author><category term="biology," /><category term="AML" /><summary type="html"><![CDATA[Our collaborative project titled “NPM1 Mutation Specific Therapeutic Vulnerabilities in Acute Myeloid Leukemia” has been selected as an awardee for Hematologic Malignancies Translational Research Team (HM-TRT) Pilot Funding FY2026 ($25,000). This project is a collaboration between Dr. Francine Garrett-Bakelman, Dr. Subhash Prajapati and P3SysBioLab. Our undergraduate, Beckett Lisle contributed to the proposal and will work on this project. Congratulations Team!]]></summary></entry><entry><title type="html">Media Feature</title><link href="https://www.p3sysbiolab.org/2025/12/25/MediaFeature.html" rel="alternate" type="text/html" title="Media Feature" /><published>2025-12-25T00:00:00+00:00</published><updated>2026-02-14T13:47:29+00:00</updated><id>https://www.p3sysbiolab.org/2025/12/25/MediaFeature</id><content type="html" xml:base="https://www.p3sysbiolab.org/2025/12/25/MediaFeature.html"><![CDATA[<p>Our research identifying high-risk AML patients got featured on local news.</p>

<p>More details here:<br />
<a href="https://www.youtube.com/watch?v=REMu4fNQPeY">UVA Researchers’ Blood Cancer Discovery Identifies High-Risk Patients and Could Improve Outcomes</a></p>]]></content><author><name>BB Paudel</name></author><category term="biology," /><category term="medicine" /><summary type="html"><![CDATA[Our research identifying high-risk AML patients got featured on local news.]]></summary></entry><entry><title type="html">NCI P01 Awarded</title><link href="https://www.p3sysbiolab.org/2025/12/23/GrantNews.html" rel="alternate" type="text/html" title="NCI P01 Awarded" /><published>2025-12-23T00:00:00+00:00</published><updated>2026-02-14T13:47:29+00:00</updated><id>https://www.p3sysbiolab.org/2025/12/23/GrantNews</id><content type="html" xml:base="https://www.p3sysbiolab.org/2025/12/23/GrantNews.html"><![CDATA[<p>Our collaborative team at UVA has been awarded a five-year NCI P01 grant to lead a national study seeking new treatments for Acute Myeloid Leukemia.</p>

<p>More details here:<br />
<a href="https://news.med.virginia.edu/research/uva-research-team-awarded-13-million-to-lead-national-study-seeking-new-treatments-for-acute-myeloid-leukemia/">UVA Research Team Awarded $13M NCI P01 for AML Study</a></p>]]></content><author><name>BB Paudel</name></author><summary type="html"><![CDATA[Our collaborative team at UVA has been awarded a five-year NCI P01 grant to lead a national study seeking new treatments for Acute Myeloid Leukemia.]]></summary></entry><entry><title type="html">Paper Featured</title><link href="https://www.p3sysbiolab.org/2025/12/23/News1.html" rel="alternate" type="text/html" title="Paper Featured" /><published>2025-12-23T00:00:00+00:00</published><updated>2026-02-14T13:47:29+00:00</updated><id>https://www.p3sysbiolab.org/2025/12/23/News1</id><content type="html" xml:base="https://www.p3sysbiolab.org/2025/12/23/News1.html"><![CDATA[<p>Our research paper published in <em>Blood Advances</em> is highlighted in UVA News.</p>

<p>More details here:<br />
<a href="https://news.med.virginia.edu/research/uva-researchers-blood-cancer-discovery-identifies-high-risk-patients-could-improve-outcomes/">UVA Researchers’ Blood Cancer Discovery Identifies High-Risk Patients and Could Improve Outcomes</a></p>]]></content><author><name>BB Paudel</name></author><category term="biology," /><category term="medicine" /><summary type="html"><![CDATA[Our research paper published in Blood Advances is highlighted in UVA News.]]></summary></entry><entry><title type="html">Grant awarded</title><link href="https://www.p3sysbiolab.org/2025/02/18/GrantNews-2.html" rel="alternate" type="text/html" title="Grant awarded" /><published>2025-02-18T00:00:00+00:00</published><updated>2026-02-14T13:47:29+00:00</updated><id>https://www.p3sysbiolab.org/2025/02/18/GrantNews-2</id><content type="html" xml:base="https://www.p3sysbiolab.org/2025/02/18/GrantNews-2.html"><![CDATA[<p>P3SysBioLab’s grant titled “Sphingolipid-Based Stratification and Therapeutic Targeting in Acute Myeloid Leukemia” has been selected as an awardee for American Cancer Society Institutional Research Grant (ACS-IRG) FY2025 ($50,000). We will develeop surface marker panels for sphingolipid-based subtyping in AML, and identify therapeutic vulnerabilities within sphingolipid metabolic pathway.</p>]]></content><author><name>BB Paudel</name></author><category term="biology," /><category term="AML" /><summary type="html"><![CDATA[P3SysBioLab’s grant titled “Sphingolipid-Based Stratification and Therapeutic Targeting in Acute Myeloid Leukemia” has been selected as an awardee for American Cancer Society Institutional Research Grant (ACS-IRG) FY2025 ($50,000). We will develeop surface marker panels for sphingolipid-based subtyping in AML, and identify therapeutic vulnerabilities within sphingolipid metabolic pathway.]]></summary></entry></feed>